Serum amyloid A is an exchangeable apolipoprotein

Patricia G. Wilson, Joel C. Thompson, Preetha Shridas, Patrick J. McNamara, Maria C. De Beer, Frederick C. De Beer, Nancy R. Webb, Lisa R. Tannock

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Objective-SAA (serum amyloid A) is a family of acute-phase reactants that have proinflammatory and proatherogenic activities. SAA is more lipophilic than apoA-I (apolipoprotein A-I), and during an acute-phase response, <10% of plasma SAA is found lipid-free. In most reports, SAA is found exclusively associated with high-density lipoprotein; however, we and others have reported SAA on apoB (apolipoprotein B)-containing lipoproteins in both mice and humans. The goal of this study was to determine whether SAA is an exchangeable apolipoprotein. Approach and Results-Delipidated human SAA was incubated with SAA-free human lipoproteins; then, samples were reisolated by fast protein liquid chromatography, and SAA analyzed by ELISA and immunoblot. Both in vitro and in vivo, we show that SAA associates with any lipoprotein and does not remain in a lipid-free form. Although SAA is preferentially found on high-density lipoprotein, it can exchange between lipoproteins. In the presence of CETP (cholesterol ester transfer protein), there is greater exchange of SAA between lipoproteins. Subjects with diabetes mellitus, but not those with metabolic syndrome, showed altered SAA lipoprotein distribution postprandially. Proteoglycan-mediated lipoprotein retention is thought to be an underlying mechanism for atherosclerosis development. SAA has a proteoglycan-binding domain. Lipoproteins containing SAA had increased proteoglycan binding compared with SAA-free lipoproteins. Conclusions-Thus, SAA is an exchangeable apolipoprotein and increases apoB-containing lipoproteins' proteoglycan binding. We and others have previously reported the presence of SAA on low-density lipoprotein in individuals with obesity, diabetes mellitus, and metabolic syndrome. We propose that the presence of SAA on apoB-containing lipoproteins may contribute to cardiovascular disease development in these populations. Visual Overview-An online visual overview is available for this article.

Original languageEnglish
Pages (from-to)1890-1900
Number of pages11
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume38
Issue number8
DOIs
StatePublished - 2018

Bibliographical note

Publisher Copyright:
© 2018 American Heart Association, Inc.

Funding

These studies were supported by funding from the Department of Veterans Affairs CX000975 (to L.R. Tannock) and CX000773 (to N.R. Webb) and from the National Institutes of Health HL134731 (to N.R. Webb and F.C. de Beer) and used core facilities supported by P30 GM103527. The contents of the publication are solely the responsibility of the authors and do not represent the official views of the US Department of Veterans Affairs, the National Institutes of Health, or the US Government.

FundersFunder number
National Institutes of Health (NIH)
National Institute of General Medical SciencesP20GM103527
U.S. Department of Veterans AffairsHL134731, CX000975, CX000773

    Keywords

    • Animal
    • Apolipoproteins
    • Atherosclerosis
    • Inflammation
    • Metabolic syndrome
    • Models

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Serum amyloid A is an exchangeable apolipoprotein'. Together they form a unique fingerprint.

    Cite this